Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty ImagesSOPA Images/LightRocket via Getty ImagesHalozyme Therapeutics (HALO) stock could be a solid choice to leverage the current momentum. Why? Because it offers strong margins, a low-debt capital structure, reasonable valuation, and strong momentum. Here are some key data points.Revenue Growth: Halozyme Therapeutics experienced revenue growth of 35.0% LTM and 35.5% over the last 3 years’ average.Long-Term Profitability: Approximately 44. ...